Birkinshaw, Richard W. http://orcid.org/0000-0003-1825-0182
Gong, Jia-nan
Luo, Cindy S.
Lio, Daisy
White, Christine A. http://orcid.org/0000-0001-8033-9140
Anderson, Mary Ann
Blombery, Piers
Lessene, Guillaume http://orcid.org/0000-0002-1193-8147
Majewski, Ian J.
Thijssen, Rachel
Roberts, Andrew W. http://orcid.org/0000-0002-7341-5720
Huang, David C. S.
Colman, Peter M.
Czabotar, Peter E. http://orcid.org/0000-0002-2594-496X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1059331, 1079706, 11131233, 1113577, 1156024, 1079560, 1116934, 1079700)
Leukemia and Lymphoma Society (SCOR 7015-18)
Victorian Cancer Agency (NA)
Cancer Council Victoria (1124178)
Article History
Received: 28 February 2019
Accepted: 8 May 2019
First Online: 3 June 2019
Competing interests
: R.W.B., J.-N.G., C.S.L., D.L., C.A.W., M.A.A., G.L., I.J.M., R.T., A.W.R., D.C.S.H., P.M.C. and P.E.C. are employees of the Walter and Eliza Hall Institute, which has an agreement with Genentech and AbbVie and receives milestone and royalty payments related to venetoclax. Employees of Walter and Eliza Hall Institute may be eligible for financial benefits related to these payments. J.-N.G., M.A.A., G.L., I.J.M., A.W.R., D.C.S.H., P.M.C. and P.E.C. receive such a financial benefit as a result of previous research related to venetoclax. G.L., D.C.S.H., P.M.C. and P.E.C. have received research funding from Genentech. A.W.R has received research funding from AbbVie. The remaining author declares no competing interests.